Newron meets with FDA over US trial enrollment hold
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Newron Pharmaceuticals SpA (NWRN)
Newron Pharmaceuticals SpA stock price live, this page displays SIX NWRN stock exchange data. View the NWRN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Newron Pharmaceuticals SpA real time stock price chart below.
What Is the Newron Pharmaceuticals SpA Stock Price Today?
The Newron Pharmaceuticals SpA stock price today is 11,36.
What Is the Stock Symbol for Newron Pharmaceuticals SpA?
The stock symbol for Newron Pharmaceuticals SpA is "NWRN."
What Stock Exchange Does Newron Pharmaceuticals SpA Trade On?
Newron Pharmaceuticals SpA is listed and trades on the Switzerland stock exchange.
Is Newron Pharmaceuticals SpA a Good Stock to Buy?
Determining whether Newron Pharmaceuticals SpA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NWRN quote. (ISIN: IT0004147952)
What Is the Newron Pharmaceuticals SpA Stock Price Today?
The Newron Pharmaceuticals SpA stock price today is 11,36.
What Is the Stock Symbol for Newron Pharmaceuticals SpA?
The stock symbol for Newron Pharmaceuticals SpA is "NWRN."
What Stock Exchange Does Newron Pharmaceuticals SpA Trade On?
Newron Pharmaceuticals SpA is listed and trades on the Switzerland stock exchange.
Is Newron Pharmaceuticals SpA a Good Stock to Buy?
Determining whether Newron Pharmaceuticals SpA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NWRN quote. (ISIN: IT0004147952)
11.36
-0.04(-0.35%)
Delayed Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.30
11.50
52 wk Range
8.83
31.85
NWRN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.3011.50
52 wk Range
8.8331.85
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
NWRN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
47.85
Upside
+321.18%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 47.85
(+321.18% Upside)
Earnings
Latest Release
Sep 16, 2025
EPS / Forecast
-- / -0,50
Revenue / Forecast
11,9M / --
Compare NWRN to Peers and Sector
Metrics to compare | NWRN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNWRNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −19.0x | −0.4x | −0.3x | |
PEG Ratio | 0.10 | 0.00 | 0.00 | |
Price/Book | −22.6x | 1.7x | 2.6x | |
Price / LTM Sales | 13.1x | 3.9x | 3.0x | |
Upside (Analyst Target) | 259.1% | 79.6% | 53.8% | |
Fair Value Upside | Unlock | 12.6% | 8.6% | Unlock |
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. It has a strategic partnership with Zambon and Meiji Seika Pharma Co., Ltd. for the commercialization of safinamide. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Newron Pharmaceuticals (NWRN) Stock Price Today?
The Newron Pharmaceuticals stock price today is 11,36 CHF.
What Stock Exchange Does Newron Pharmaceuticals Trade On?
Newron Pharmaceuticals is listed and trades on the Switzerland Stock Exchange.
What Is the Stock Symbol for Newron Pharmaceuticals?
The stock symbol for Newron Pharmaceuticals is "NWRN."
What Is the Newron Pharmaceuticals Market Cap?
As of today, Newron Pharmaceuticals market cap is 236,35M CHF.
What Is Newron Pharmaceuticals's Earnings Per Share (TTM)?
The Newron Pharmaceuticals EPS (TTM) is -0,66.
From a Technical Analysis Perspective, Is NWRN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Newron Pharmaceuticals Stock Split?
Newron Pharmaceuticals has split 0 times.
How Many Employees Does Newron Pharmaceuticals Have?
Newron Pharmaceuticals has 27 employees.
What is the current trading status of Newron Pharmaceuticals (NWRN)?
As of Sep 11, 2026, Newron Pharmaceuticals (NWRN) is trading at a price of 11,36 CHF, with a previous close of 11,40 CHF. The stock has fluctuated within a day range of 11,30 CHF to 11,50 CHF, while its 52-week range spans from 8,83 CHF to 31,85 CHF.
What Is Newron Pharmaceuticals (NWRN) Price Target According to Analysts?
The average 12-month price target for Newron Pharmaceuticals is 47,85 CHF, with a high estimate of 73.23299047 CHF and a low estimate of 36.02529018 CHF. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +321,18% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.